Granite Point Capital Management, L.P. Neurocrine Biosciences Inc Transaction History
Granite Point Capital Management, L.P.
- $0
- Q3 2023
A detailed history of Granite Point Capital Management, L.P. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Granite Point Capital Management, L.P. holds 150,000 shares of NBIX stock, worth $20.7 Million. This represents 1.1% of its overall portfolio holdings.
Number of Shares
150,000Holding current value
$20.7 Million% of portfolio
1.1%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding NBIX
# of Institutions
626Shares Held
94MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.96 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.38 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$710 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$355 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$257 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $13.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...